GICS Sector : Healthcare
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics.The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake.It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Nov -14
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Nov -07
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Oct -29
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Oct -28
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Aug -26
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
Aug -12
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Aug -12
Biora Therapeutics Announces Funding Agreement with Existing Investors
Aug -12
Growing demand for non-invasive cancer diagnostics, increasing adoption of precision medicine, and advancements in gut-derived biomarkers drive the growth of Molecular Testing Products from Biora Therapeutics, Inc.
A minimally invasive, implantable device that uses bioelectronic medicine to treat various diseases and conditions, such as inflammatory bowel disease, rheumatoid arthritis, and others.
A non-pharmacological approach that uses electrical impulses to modulate the nervous system and treat various conditions, such as chronic pain, inflammatory bowel disease, and others.
Implantable devices that use bioelectronic medicine to treat various diseases and conditions, such as inflammatory bowel disease, rheumatoid arthritis, and others.
Therapies that target neuroinflammation to treat various diseases and conditions, such as multiple sclerosis, Alzheimer's disease, and others.
Biora Therapeutics, Inc. has a low threat of substitutes due to its unique and patented technology in the field of bioelectronic medicine.
The bargaining power of customers is moderate, as Biora Therapeutics, Inc. has a diverse customer base, but some large customers may have significant negotiating power.
The bargaining power of suppliers is low, as Biora Therapeutics, Inc. has a diverse supplier base and is not heavily dependent on any single supplier.
The threat of new entrants is high, as the bioelectronic medicine industry is rapidly growing and attracting new entrants with innovative technologies.
The intensity of rivalry is moderate, as Biora Therapeutics, Inc. operates in a competitive industry, but has a strong market position and differentiated products.
| Value | |
|---|---|
| Debt Weight | -85.03% |
| Debt Cost | 10.08% |
| Equity Weight | 185.03% |
| Equity Cost | 10.08% |
| WACC | 10.08% |
| Leverage | -45.95% |
Value: 7.4
Growth: 8.0
Quality: 7.0
Yield: 0.0
Momentum: 10.0
Volatility: 1.0
1-Year Total Return ->
Value: 2.2
Growth: 7.1
Quality: 4.6
Yield: 0.0
Momentum: 10.0
Volatility: 2.7
1-Year Total Return ->
Value: 7.8
Growth: 4.8
Quality: 3.0
Yield: 0.0
Momentum: 6.0
Volatility: 3.0
1-Year Total Return ->
Value: 9.6
Growth: 5.4
Quality: 5.2
Yield: 0.0
Momentum: 0.5
Volatility: 2.0
1-Year Total Return ->
Value: 8.8
Growth: 3.4
Quality: 5.2
Yield: 0.0
Momentum: 0.0
Volatility: 0.3
1-Year Total Return ->
Value: 7.0
Growth: 2.9
Quality: 2.9
Yield: 0.0
Momentum: 2.0
Volatility: 0.3
1-Year Total Return ->